Tuesday, March 2, 2010

Anthrax PA Antibody

Anthrax PA Antibody

Catalog# : 3411

Anthrax infection is initiated by the inhalation, ingestion, or cutaneous contact with Bacillus anthracis endospores. B. anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF), and edema factor (EF) (1,2 for review). PA binds to two related proteins on the cell surface; these are termed tumor epithelial marker 8 (TEM8)/anthrax toxin receptor (ATR) (3) and capillary morphogenesis protein 2 (CMG2) (4), although it is still unclear which is physiologically relevant. Following PA binding to its receptor, PA is cleaved into two fragments by a furin-like protease. The bound fragment binds both LF and EF; the resulting complex is then endocytosed which allows the translocation of LF and EF into the cytoplasm (5). These toxins are usually sufficient to cause rapid cell death, and often the death of the organism.

Additional Names : Anthrax PA (IN), Anthrax PA

Source : Anthrax PA antibody was raised against a synthetic peptide corresponding to 16 amino acids in the middle of the Anthrax protective antigen protein.

Purification : Affinity chromatography purified via peptide column

Clonality and Clone : This is a polyclonal antibody.

Host : Anthrax PA antibody was raised in rabbit.

Immunogen : Human Anthrax PA (Intermediate Domain) Peptide (Cat. No. 3411P)

Application : Anthrax PA antibody can be use

Tested Application(s) : E

Buffer : Antibody is supplied in PBS containing 0.02% sodium azide.

Blocking Peptide : Cat. No. 3411P - Anthrax PA Peptide

Long-Term Storage : Anthrax PA antibody can be stored at 4ºC, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Species Reactivity :Bac

GI Number : 9280533

Accession Number : AAF86457

Short Description : (IN) Anthrax protective antigen

References
  1. Schwartz MN. Recognition and management of anthrax – an update. New Engl. J. Med. 2001; 345:1621-6.
  2. Moayeri M and Leppla SH. The roles of anthrax toxin in pathogenesis. Curr. Opin. Microbiol. 2004; 7:19-24.
  3. Bradley KA, Mogridge J, Mourez M, et al. Identification of the cellular receptor for anthrax toxin. Nature 2001; 414:225-9.
  4. Scobie HM, Rainey GJ, Bradley KA, et al. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA 2003; 100:5170-4.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis

Anthrax Lethal Factor Antibody

Anthrax Lethal Factor Antibody

Catalog# : 3415

Anthrax infection is initiated by the inhalation, ingestion, or cutaneous contact with Bacillus anthracis endospores. B. anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF), and edema factor (EF) (1,2 for review). PA binds to two related proteins on the cell surface; these are termed tumor epithelial marker 8 (TEM8)/anthrax toxin receptor (ATR) (3) and capillary morphogenesis protein 2 (CMG2) (4), although it is still unclear which is physiologically relevant. Following PA binding to its receptor, PA is cleaved into two fragments by a furin-like protease. The bound fragment binds both LF and EF; the resulting complex is then endocytosed which allows the translocation of LF and EF into the cytoplasm (5). LF is the primary toxin of anthrax and functions as a highly specific protease that cleaves members of the mitogen-activated protein kinase kinase (MAPKK) family near their amino terminus, interfering with MAPK signaling and inducing apoptosis (6).

Additional Names : Anthrax Lethal Factor (IN), Anthrax LF

Source : Anthrax lethal factor antibody was raised against a synthetic peptide corresponding to 16 amino acids in the middle of the Anthrax lethal factor protein.

Purification : Affinity chromatography purified via peptide column

Clonality and Clone : This is a polyclonal antibody.

Host : Anthrax Lethal Factor antibody was raised in rabbit.

Immunogen : Anthrax Lethal Factor (Intermediate Domain) Peptide (Cat. No. 3415P)

Application : Anthrax lethal factor antibody

Tested Application(s) : E

Buffer : Antibody is supplied in PBS containing 0.02% sodium azide.

Blocking Peptide : Cat. No. 3415P - Anthrax Lethal Factor Peptide

Long-Term Storage : Anthrax Lethal Factor antibody can be stored at 4ºC, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Species Reactivity : Bac

GI Number : 50402185

Accession Number : P15917

Short Description : (IN) Anthrax lethal factor

References
  1. Schwartz MN. Recognition and management of anthrax – an update. New Engl. J. Med. 2001; 345:1621-6.
  2. Moayeri M and Leppla SH. The roles of anthrax toxin in pathogenesis. Curr. Opin. Microbiol. 2004; 7:19-24.
  3. Bradley KA, Mogridge J, Mourez M, et al. Identification of the cellular receptor for anthrax toxin. Nature 2001; 414:225-9.
  4. Scobie HM, Rainey GJ, Bradley KA, et al. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA 2003; 100:5170-4.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis

Anthrax Edema Factor Antibody

Anthrax Edema Factor Antibody

Catalog# : 3419

Anthrax infection is initiated by the inhalation, ingestion, or cutaneous contact with Bacillus anthracis endospores. B. anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF), and edema factor (EF) (1,2 for review). PA binds to two related proteins on the cell surface; these are termed tumor epithelial marker 8 (TEM8)/anthrax toxin receptor (ATR) (3) and capillary morphogenesis protein 2 (CMG2) (4), although it is still unclear which is physiologically relevant. Following PA binding to its receptor, PA is cleaved into two fragments by a furin-like protease. The bound fragment binds both LF and EF; the resulting complex is then endocytosed which allows the translocation of LF and EF into the cytoplasm (5). EF is a calmodulin and Ca++-dependent adenylate cyclase responsible for the edema seen in the disease. It is thought to benefit the B. anthracis bacteria by inhibiting cells of the host immune system (reviewed in 6).

Additional Names : Anthrax Edema Factor, Anthrax EF

Source : Anthrax Edema Factor antibody was raised against a synthetic peptide corresponding to 16 amino acids near the carboxy terminus of the Anthrax edema factor protein.

Purification : Affinity chromatography purified via peptide column

Clonality and Clone : This is a polyclonal antibody.

Host : Anthrax Edema Factor antibody was raised in rabbit.

Immunogen : Anthrax Edema Factor Peptide (Cat. No. 3419P)

Application : Anthrax Edema Factor antibody

Tested Application(s) : E

Buffer : Antibody is supplied in PBS containing 0.02% sodium azide.

Blocking Peptide : Cat. No. 3419P - Anthrax Edema Factor Peptide

Long-Term Storage : Anthrax Edema Factor antibody can be stored at 4ºC, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Species Reactivity : Bac

GI Number : 729244

Accession Number : P40136

Short Description : Anthrax edema factor

References
  1. Schwartz MN. Recognition and management of anthrax – an update. New Engl. J. Med. 2001; 345:1621-6.
  2. Moayeri M and Leppla SH. The roles of anthrax toxin in pathogenesis. Curr. Opin. Microbiol. 2004; 7:19-24.
  3. Bradley KA, Mogridge J, Mourez M, et al. Identification of the cellular receptor for anthrax toxin. Nature 2001;
  4. Scobie HM, Rainey GJ, Bradley KA, et al. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA 2003; 100:5170-4.
For more detail regarding Peptide please visit here : Custom Peptide Synthesis

Abundant Serum Protien Depletion Kit

Abundant Serum Protien Depletion Kit

Catalog# : NB-17300
Price/Unit : $220.00
Unit : 25 preps

This Depletion Kit provides a fast and simple procedure for the effective depletion of major serum proteins including albumin , alpha -antitrypsin, transferin and haptoglobin from serum and plasma samples. The kit is unique in that it is based on an ion-exchange mechanism and not the use of specific antibodies. As a result, the kit can be used to deplete serum proteins from a wide variety of samples, including human and various animals.

Each spin column can deplete up to 500 µg of serum proteins. Albumin has been found to be depleted by 70%, transferrin and haptoglobin by 50% and alpha -antitrypsin by 90%. The complexity of the sample is thus greatly reduced, allowing for the detection of less abundant proteins present in the sample. Eluted samples are ready for use in various downstream applications including 2D gel electrophoresis, LC/MS and microarrays.

ProteoSpin™ Abundant Serum Protein Depletion Kit Benefits

  • Efficient removal of highly abundant proteins - The kit depletes 70% of albumin, 90% of alpha-antitrypsin, and 50% of transferrin and haptoglobin, enabling the visualization of low abundance proteins..
  • Fast and easy processing - Efficiently process up to 10 samples in less than 30 minutes using an easy-to-use protocol.
  • Does not rely on antibodies - Based on an ion exchange mechanism, the kit can be applied to serum and plasma samples from a range of sources, including human and various animals.
  • Complete Kit -All columns and solutions required are provided.
  • Low price per column - Compared to columns based on antibodies, these ion-exchange columns are much lower in price, yet perform to the same high standards.
  • Depletion of proteins and salts - Most proteins bind to the column, while salts and many of the major proteins are removed in the flowthrough.
  • Suitable for downstream applications - Final elution suitable for:
  • SDS-PAGE
  • 2D gel electrophoresis
  • LC/MS
  • Protein
ProteoSpin™ Abundant Serum Protein Depletion Kit Contents

Each ProteoSpin™ Abundant Serum Protein Depletion Kit provides essential components for use with the provided protocols.

  • Column Activation and Wash Buffer
  • Elution Buffer
  • Neutralizer
  • Mini Spin Columns
  • Elution Tubes
  • Short Protocol Card
  • Application Manual
Customer-supplied Reagents and Equipment

  • Benchtop microcentrifuge
  • Micropipettors

Figure 1. Abundant proteins are depleted from human serum to a large degree using the ProteoSpin™ Abundant Serum Protein Depletion Kit. Lane A represents the input human serum proteins, while Lanes C and D represent the elution after the abundant proteins were depleted with the kit. Lane B represents the binding flowthrough, and contains the proteins that have been depleted from the serum sample.

Figure 2. A 2D gel was run after the abundant serum proteins were depleted from human serum using the ProteoSpin™ Abundant Serum Protein Depletion Kit. The abundant proteins including albumin, alpha-antitrypsin, transferrin and haptoglobin have been removed from the sample, allowing the visualization and detection of the lower abundance proteins of interest.

Product Usage
For laboratory research use only, not for diagnostic use! Not for use in humans.

For more detail regarding Peptide please visit here : Custom Peptide Synthesis

HLA DNA typing – Disease Association

HLA or “human leukocyte antigen” system is the major histocompatibility complex (MHC) in humans, which includes several hundreds of genes located in a highly polymorphic region of chromosome 6 that encode for proteins critical for the immune system [1]. Historically, these proteins are called antigens because of their discovery as crucial factors in tissue rejection by the host, a critical matter of in organ transplantations. Thus, typing of the HLAs from donor and recipient, allows matching those with the highest similarities between their HLA genes or alleles to minimize the chances of rejection; an application that is still the most important for HLA typing. In fact, the HLA profile defines the cells from an individual or “self”, distinguishing them from those from other individuals showing a different HLA profile, “non-self”. As indicated, HLAs play a critical role in the immune system, particularly in antigen presentation, the process by which macrophages and dendritic cells or antigen presenting cells, process antigens for recognition by T cells. The two main HLA groups involved in antigen presentation are the Class I and Class II antigens that have different immunological roles.

HLA Class I antigens (A, B and C) transport and present peptides produced by degradation of proteins inside the cell, i.e. endogenous antigens such as viral antigens, to CD8+ T cells (killer T cells) that seek and destroy only those cells that in addition to the HLA Class I, carry also foreign or not-self antigens (T cell immunity). Under normal conditions, these killer T cells recognize but do not destroy those cells with the right “self” tag, i.e. HLA-I, unless they also carry a non-self antigen. Yet, under pathological conditions, like in certain autoimmune conditions, killer T cells can destroy cells carrying self-antigens, causing damage to the body.

In contrast to HLA-Class I, the role of HLA Class II antigens (DRB1, DRB3,4,5, DQA1/DQB1, DPB1) is to present the peptides from processed proteins that are produced outside the cell, exogenous antigens derived from sources like bacteria and protozoa, to helper T-cells to stimulate their multiplication. These helper T cells then stimulate B-cells to produce antibodies against the foreign antigens (humoral immunity) [2].

Although HLA typing is largely use to match organ donors and recipients, advances in the biomedical field has allowed the typing techniques to become more accurate and yield more detail information. Studies using this new information have made obvious the fact that there are significant correlations between certain HLA types and specific diseases. Consequently, HLA typing is becoming a tool to screen susceptibility to certain autoimmune diseases, as a factor affecting the prognosis of certain autoimmune and infectious diseases. However, the association between HLA type and most infectious diseases is not very clear because of the multiplicity of factors that can affect their outcome. Nevertheless, in some cases such a relation is obvious, a situation that may be helpful in establishing either the resistance or susceptibility to certain infectious diseases and even a prognosis of the disease progression [3]. Another area in which HLA typing is becoming quite important is cancer, a class of diseases where HLAs can play a role in increasing susceptibility and resistance, as well as in tumor cells evading immune surveillance. Moreover, in some cases, the HLA type shows a good correlation with the prognosis of the disease upon treatment. Here, we would discuss the different applications of HLA DNA-typing to autoimmune, infectious diseases and cancer.

Autoimmune diseases

As previously indicated, the immune system under normal conditions is usually tolerant to cells carrying “self” HLAs, i.e. it does not mount an immune response against them. Yet, in many cases, there is a mild low level of autoimmunity that presumably allows immune surveillance by the immune system and the destruction of newly formed cancer cells. Although apparently there are several genes suspected to be involved in autoimmunity, there is strong evidence that certain inherited HLAs are involved in certain specific autoimmune diseases. Because of their important role in the presentation of processed antigens to T cells, HLAs are in a unique position to modify the immune response and cause autoimmunity. HLAs can determine which antigenic peptides are bound for presentation to the immune system, thus it can present “self” peptides auto reactive T cells. In other cases, certain HLAs may bind peptides from infectious agents that share some similarities to the self-antigens to generate an immune response against self-antigens; this molecular mimicry often leads to autoimmunity. In fact, several HLAs, like HLA-B27, are associated with various autoimmune inflammatory diseases. Some of these autoimmune diseases, their association to specific HLAs, and the relative risk of acquiring the disease as a function of specific HLAs are briefly discuss here.

Rheumatoid Arthritis. An inflammatory disease that is the result of a complex immune cascade and that its susceptibility is dependent on the presence of HLA-DR4 and HLA-DRB1 [4]. Presence of these HLA types increases the risk factor of contracting the disease 7-fold when compared to that population not carrying these HLA genes. In Peruvian mestizo patients the HLA allele DRB1*1402 is associated with a significant risk of contracting the disease.

Post-infectious Arthritis. An inflammatory condition of the joints, triggered by gastrointestinal or genitourinary bacterial infections or by a viral infection. Although it is assume that the synovial fluid is sterile, studies using PCR had detected bacterial DNA in the fluid. It has been found that individuals that suffer of this disease carry the gene for HLA-B27 and that the risk factor increases 10 to 20-fold [5]. Diagnosis is usually made by examining the synovial fluid for the presence of pathogenic antigens or DNA. However¸ detection of the HLA-B27 gene should be an effective confirmatory test.

Type I Diabetes. A disease strongly linked to HLA genes, however, the relative importance of the different HLA genes involve is quite complex and changing with new discoveries in the area. Moreover, in addition to the HLA genes there are other unrelated genes that play a role in the susceptibility to contract the disease. The HLA-DR3 and DR4 genes have been identified as playing important roles and that the presence of any of these two genes increases the risk of contracting the disease 5-6-fold, while the presence of both genes increases the risk factor to 15 [6]. Yet, new research indicates that some HLA-DQ genes play a role in susceptibility to the disease that is even higher than that of the DR genes.

Autoimmune Hepatitis. An inflammation of the liver due to unknown causes that raises the possibility that the chronic hepatitis observed in many patients may be in many cases due to an autoimmune reaction. The incidence of autoimmune hepatitis in South America although not well established it is apparently significant. Like other autoimmune diseases, there are genetic factors that affect its occurrence, e.g. HLAs; however, different ethnic groups have different susceptibility alleles. For instance, in South America is HLA DRB1*1301 while in Europe is HLA DR3. These HLAs have significant differences in their sequences within the antigen binding grove of the HLA DR molecule [7]. This fact strongly suggests that perhaps an unidentified indigenous etiologic agent must be the cause of autoimmune hepatitis in South America.

Celiac Disease. This autoimmune disorder of the small intestine is triggered by gluten proteins that occur in genetically predisposed people. The condition causes chronic diarrhea, fatigue and other problems, with the only effective therapy being a gluten-free diet. Although for some time it was assumed that the disease was limited to Europeans, recently it has been established that this condition is worldwide spread. For instance, the prevalence of this condition in Peru is estimated to around 0.40% or 1 of every 250 people, a prevalence quite similar to that of the US and many European countries. Over 95% of the celiac patients have some isoform of HLA-DQ2 or DQ8, however, their frequency varies geographically around the world. In effect, in South America where DQ8 accounts for 90% of the phenotype, the dominant HLA associated with celiac disease is DQ8 [8].

There are other autoimmune conditions with a strong association with HLAs, such as: Ankylosing Spondylitis associated to HLA B27; Narcolepsy a neurological disease closely associated with the HLA-DQB1*0602, i.e. over 90% of the patients carry this gene, but 20% of the population carry this gene, a situation that indicates the role of other factors in triggering this disease; Primary Sjögren Syndrome, in South America the HLA-DRB1*0301-DQB1*0201 haplotype is associated with the disease and apparently plays a role in the production of autoantibodies [9].

Infectious diseases

HLAs’ crucial role in mounting an immune response is show by the fact, that in many vaccines the nature of an individual’s HLA profile decides the production of an effective or ineffective immune response. In many cases, the susceptibility, resistance and progression of an infectious disease show an association with the individual’s genetic HLA profile. Perhaps the best study diseases are those caused by Mycobacteria, i.e. M. tuberculosis and M. leprae, in both cases the form of disease is link to the HLA profile. In tuberculosis the severity of the disease is associated with HLA DR2, i.e. the DR2 patients have a strong antibody response but a low T cell immunity, the later being the protective response against tuberculosis [10]. Consequently, the HLA DR2 does not only increase the susceptibility to the disease, but it also affects its progression. Yet, it is apparent that besides the HLA component, there are also other factors deciding TB susceptibility. A brief review of some infections associated with certain HLAs is given here.

Malaria. The association between HLA class I-B53 and protection from severe malaria is well established. In fact, a nonapeptide from P. falciparum hepatic phase that is HLA-B53 restricted and recognized by cytotoxic T lymphocytes (CTL) has been identify, which provides the bases to explain the killing of infected cells by (CTLs) [11]. This finding supports the approach of using the hepatic phase of the parasite to develop an effective vaccine.

Hepatitis B and C. The hepatitis B virus (HBV) is worldwide the major cause of chronic hepatitis and hepatocellular carcinoma. HLA-Class II DR1*1301-02 has been identified as being associated with resistance to infection by HBV and protection against chronic hepatitis [12]. The same allele has been associated with protection against chronic hepatitis due to hepatitis C virus (HCV).

Epstein-Barr Virus (EBV). The etiological agent of infectious mononucleosis that infects B cells, in addition to CD21 needs HLA Class II-DR, to enter the cell. It has been show that HLA-DR can be substitute by HLA-DP or a subset of HLA-DQ as co-receptors for EBV. These findings raise the possibility that individuals expressing HLA-DR, -DP or –DQ, are susceptible to EBV infection [13].

Cancer

Like in the case of autoimmune diseases, there are clear associations between some cancer’s resistance or susceptibility and the classic HLA profile of an individual. Like in autoimmunity, the HLA profile is largely dependent on the ethnic group, particularly in the cases where cancer is trigger by an infectious agent, e.g. virus and bacteria. The role of HLA in resistance or susceptibility to cancer is not well understood, but it is possible that because of their role in immunity they influence the immune surveillance process. Nevertheless, independent of their role, it has been show that HLAs are associated with either susceptibility or resistance to certain cancers. In addition to the classical HLAs, a non-classic HLA, HLA-G, is becoming relevant to cancer development, as well as a new biomarker for tumor cells [14]. Following is a brief discussion of two cancers quite common in Peru where HLA can affect their development.

Breast cancer. There are many genes unrelated to HLAs that affect the susceptibility to breast cancer. However, in the US two HLA Class II genes, HLA DQB*03032 and HLA DRB1*11, have been identified that may have a protective role in human breast cancer in Caucasians [15].

Cervical cancer. This cancer is cause by infection with several strains of human papilloma virus(HPV) with HPV16 being one of the most oncogenic. HLA typing have shown that two alleles, DQB1*0602 and DRB1*1501, are associated with the presence of cancer in Hispanic patients [16]. Apparently, these two alleles also contribute to the inability to clear HPV infection. However, there are also HLA alleles, DRB1*1301 and *1302, that protect against cancer induced by HPV infection.

HLA-G.

The expression of this non-classic HLA Class I is under epigenetic control, i.e. when the DNA is methylated the expression of HLA-G is suppressed [17]. There is evidence that HLA-G promotes tolerance during pregnancy, however, this protein is also produce by many types of cancer cells. This situation suggests that HLA-G may play some role in tumor cells evading immune surveillance by inducing tolerance of the immune system. In addition to the cell-associated HLA-G, there is a secreted, circulating form, sHLA-G, that may suppress the immune regulation of cancer cells [18]. The production of HLA-G can be a good indicator for the clinical prognosis of different cancers. As a rule, HLA-G is always associated with malignant tumor cells and it never has been found in normal cells. Thus, HLA-G appears to be a promising biomarker to predict the clinical progression of different cancers.

REFERENCES

1. Gerlach John. Arch Pathol Lab Med, 2002, 126:281-284.

2. Mingari MC et al. Hum Immunnol. 2000;61:44-50

3. Klein J et al. N. Engl. J. Med. 2000, 343:782-786

4. Weyand CN et al. Arthritis Res. 2000, 2:212-214.

5. Amital H et al. Clin Exp Rheumatol. 2008, 26:S27-32.

6. Chiu FK et al. J Endocrinol Invest. 2004, 27:480-484.

7. De Silva S et al. Liver Int. 2006, 26:509-511.

8. Green PH et al. Lancet, 2003, 362:383-391.

9. Quelvenecc E et al. Clin Exp Rheumatol. 1998, 16:725-728

10. Selvaraj P. Ind J Tub. 2000; 47:133-138.

11. Sing N. et al. Emerging Infect Dis. 1997; 3:41-49

12. Ramezani A et al. J Gastroenterol Hepatol. 2008; 23:1716-1721

13. Haan KM et al. J Virol. 2000; 74:2451-2454

14. Ie-Ming S. Hum Immunol. 2007; 68:272-276

15. Chaudhuri S et al. Proc Nat Acad Sci USA 2000; 97:11451-11454

16. Garcia Corona C. et al. Arch Dermatol. 2004; 140: 1227-1231

17. Menendez L et al. Molecular Cancer 2008; 7:43

18. Rouas-Freiss N et al. Cancer Res. 2005; 65:10139-10144

Bio-Synthesis Inc, has been producing synthetic oligonucleotides and peptides for over 25 years; not only DNA, but RNA, other modified oligonucleotides, and more recently bio-conjugates, which have a number of applications on gene expression inhibition and related anti-sense studies. Also synthetic peptides and peptide antibodies for a number of biological relevant applications, in the areas of proteomics, epigenetics, immune regulation, post translational modifications, antisense , gene expression control, RNA interference just to mention a few.

For more detail regarding Peptide please visit here : Custom Peptide Synthesis

Monday, February 22, 2010

FRET Peptides

Definition
Fluorescence resonance energy transfer (FRET) is a distance-dependent interaction between the electronic excited states of two dye molecules in which excitation is transferred from a donor molecule to an acceptor molecule without emission of a photon1. Following are some of the standard dye combinations used: a)Fluorescein and Dabcyl or Dabsyl b) Fluorescein and Tamra c) Methoxy-coumarin-acetic-acid(MCA) and 2,4-Dinitrophenyl(DNP).

Discovery
The first internally quenched fluorescent peptide reported was a substrate for angiotensin I-converting enzyme (ACE), namely Abz-Gly-Phe(NO2)-Pro where the fluorescence of the N-terminal ortho-amino benzoic acid (Abz) was quenched by the p-nitro-phenylalanine [Phe(NO2)] group (Carmel and Yaron 1978) 2. A new generation of fluorescence-quenched substrates was developed by Chagas et al., (1991), using the FRET peptide concept described substrates for tissue and plasma kallikrein containing Abz as the fluorescent group and EDDnp (2,4-dinitrophenyl ethylenediamine) as the quencher group. The FRET peptides introduced by Chagas et al., (1991) was a breakthrough in the study of proteases’ specificity, and the synthesis of different Abzpeptidyl-EDDnp sequences provided the opportunity for us to study the activity of various endopeptidases such as human rennin3.

Structural Characteristics
FRET peptides are labelled with two dye molecules. These can be identical, but in most applications, different dyes are commonly used. FRET describes the transfer of energy from an initially excited donor (dye 1) to an acceptor (dye 2). Typically, this donor emits light at a wavelength λd that overlaps with the absorption wavelength λa of the acceptor. If donor and acceptor dye are in close proximity (10 – 100 Å),

this energy transfer happens in one of two ways, depending on the chemical structure of the acceptor:

a) the transferred energy is converted to molecular vibrations (acceptor is dark quencher)

b) the transferred energy is emitted as light with a longer wavelength (acceptor is fluorescent).

Mode of Action
In a FRET peptide fluorescent donor group attached to one of the amino acid residues of the peptide transfers energy to a quenching acceptor attached to another residue in the sequence following the resonance mechanism. This process occurs whenever the emission spectrum of the fluorophore overlaps with the absorption spectrum of the acceptor (Sapsford et al., 2006)4. The FRET peptides exhibit internal fluorescence quenching when intact, but cleavage of any peptide bond between the donor/acceptor pair liberates fluorescence that can be detected continuously, allowing a quantitative measurement of the enzyme activity.

Functions
Fluorescence Energy Resonance Transfer (FRET) peptides are an excellent alternative for enzyme kinetic studies and for analysis of the enzymatic activity in biological fluids, crude tissue extracts or on the surface of cells in culture.

FRET peptides are used as suitable substrates in enzyme studies, such as:
1. Functional characterization of peptidases / proteases / kinases / phosphatases.
2. Kinetic characterization of peptidases / proteases / kinases / phosphatases.
3. Screening and detection of new proteolytic enzymes.
4. They can be used for conformational investigation of peptide folding.

References
1.Hossain MA, Mihara H, Ueno A (2003). Fluorescence resonance energy transfer in a novel cyclodextrin-peptide conjugate for detecting steroid molecules. Bioorg Med Chem Lett., 13(24):4305-4308.
2.Carmel A, Yaron A (1978). An intramolecularly quenched fluorescent tripeptide as a fluorogenic substrate of angiotensin-I-converting enzyme and of bacterial dipeptidyl carboxypeptidase. Eur J Biochem., 87(2):265-273.
3.Chagas JR, Juliano L, Prado ES (1991). Intramolecularly quenched fluorogenic tetrapeptide substrates for tissue and plasma kallikreins. Anal Biochem., 192(2):419-425.
4.Sapsford KE, Berti L, Medintz IL (2006). Materials for fluorescence resonance energy transfer analysis: beyond traditional donor-acceptor combinations. Angew Chem Int Ed Engl., 45(28):4562-4589.

Please visit our Stumbleupon Profile Bio-Synthesis

For more detail regarding Peptide please visit here : Custom Peptide Synthesis

Tuesday, February 9, 2010

Secretase Inhibitors and Substrates

Definition
ß- and g-secretases generate the amyloid ß-protein (Aß) 1 from amyloid ß-protein precursor (APP) that is the hallmark of Alzheimer disease. Gamma (g)?-secretase has also been implicated in the cleavage of other substrates, the most notable one being the Notch receptor. Inhibition of Notch processing is the key factor of mechanism-based side effects associated with g-secretase inhibitors.

Discovery
Vassar R in 2000 discussed about a beta generating enzyme in Alzheimer disease (AD) 2. Esler in 2002 carried out activity-dependent isolation of the presenilin- g-secretase complex. The functional g-secretase complex was isolated by using an immobilized active site-directed inhibitor of the protease. Presenilin heterodimers and nicastrin bound specifically to this inhibitor under conditions tightly correlating with protease activity, whereas several other presenilin-interacting proteins (beta-catenin, calsenilin, and presenilin-associated protein) did not bind. Moreover, anti-nicastrin antibodies immunoprecipitated g-secretase activity from detergent-solubilized microsomes. Unexpectedly, C83, the major endogenous amyloid-beta precursor protein substrate of g-secretase, was also quantitatively associated with the complex 3.

Structural Characteristics
AD is characterized by the progressive accumulation of Aß in brain regions subserving memory and cognition. ß-Secretase is a single membrane-spanning aspartyl pro-tease expressed at high levels in neurons 2. ?-Secretase is also an aspartyl protease but with an unprecedented intramembranous catalytic site that is required for the cleavage of a wide range of type I membrane proteins that include APP and the Notch receptors3. g-secretase is a multi-subunit protease complex, which is an integral membrane protein that cleaves single-pass transmembrane proteins. g???secretase complex consists of four individual proteins: presenilin, nicastrin, APH-1 (anterior pharynx-defective 1), and PEN-2 (presenilin enhancer 2). PEN-2 associates with the complex via binding of a transmembrane domain of presenilin. APH-1, which is required for proteolytic activity, binds to the complex via a conserved alpha helix interaction motif and aids in initiating assembly of premature components4,5. Substrate of g?? secretase is amyloid precursor protein, a large integral membrane protein that, which is cleaved by both g and b secretase, into a short 39-42 amino acid peptide known as amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of AD patients. Substrate recognition occurs via nicastrin ectodomain binding to the N-terminus of the target, which is then passed via a poorly understood process between the two presenilin fragments to a water-containing active site at which the catalytic aspartate residue resides. Structure of novel g-secretase inhibitor is [1S-benzyl-4R-[1-(5-cyclohexyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3(R,S)-ylcarbamoyl)-S-ethylcarbamoyl]-2R-hydroxy-5-phenyl-pentyl]-carbamic acid tert-butyl ester (CBAP), which not only physically interacts with presenilin 1 (PS1), but upon chronic treatment produces a "pharmacological knock-down" of PS1 fragments 6.

Mode of Action
Development of AD pathology appears to be causally related to age-dependent changes in the metabolism of the Aß, leading to its enhanced aggregation and deposition. g-Secretase is a crucial enzyme for the generation of antibody from the APP and thus represents a valid potential therapeutic target for the treatment or prevention of AD. Enzyme activity has been shown to be dependent on the expression of presenilins and the identification of inhibitors containing transition-state analogue mimics, together with mutagenesis and knockout studies, confirms that presenilins may provide at least a component of the catalytic site for this putative aspartyl protease. Considerable effort has been expended to identify compounds which specifically reduce g-secretase activity in the central nervous system, and those with the appropriate properties are being utilized in on-going proof-of-concept studies in animals and humans, to determine the extent and duration of g-secretase inhibition required to elicit therapeutic benefits. g-secretase-mediated substrate cleavage fall into the category of 'regulated intramembrane proteolysis'. g -secretase itself displays characteristics of an aspartyl protease as it is inhibited by structurally diverse transition-state mimetics for this class of protease. These include compounds with moderate affinities such as substrate-based difluoroketones or an inhibitor with potency in the low-nM range that contains a hydroxyethylene dipeptide isostere 7,8.

Functions
Cause of Alzheimer's disease, sequential action of b-secretase and g-secretase enzymes leads to releases the APP. This custom peptide entity is thought to be the cause of AD. Therefore, inhibiting either of the two critical enzymes involved in antibody peptide generation provides opportunities to develop drugs which could have the potential to slow down the progression and delay the onset of AD 9.

Gamma-secretase inhibitors may have the ability to interfere with both intermolecular and intramolecular cleavage reactions, which require presenilins. Thus, from a drug-discovery point of view it is important that g-secretase inhibitors interfere with presenilin functions 10.

Tunicamycin-induced expression of the chaperone BiP, an indicator of the unfolded protein response, was not changed in the presence of functional g-secretase inhibitors. These findings suggest that presenilins are multi-functional proteins and that gamma-secretase inhibitors are valuable tools to discriminate presenilin-associated protease functions from unrelated functions.

References
1. Selkoe DJ (2001). Alzheimer's disease: genes, proteins, and therapy. Physiol Rev., 81:741–766.Vassar R, Citron M. (2000). A beta-generating enzymes: recent advances in beta- and gamma-secretase research. Neuron, 27:419–422.
2. Esler WP, Kimberly WT, Ostaszewski BL, Ye W, Diehl TS, Selkoe DJ, Wolfe MS (2002). Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate. PNAS., 99:2720–2725.
3. Kaether C, Haass C, Steiner H. (2006). Assembly, trafficking and function of gamma-secretase. Neurodegener Dis., 3(4-5):275-283.
4. Lee SF, Shah S, Yu C, Wigley WC, Li H, Lim M, Pedersen K, Han W, Thomas P, Lundkvist J, Hao YH, Yu G (2004). A conserved GXXXG motif in APH-1 is critical for assembly and activity of the gamma-secretase complex. J Biol Chem., 279(6):4144-4152.
5. Beher D, Wrigley JD, Nadin A, Evin G, Masters CL, Harrison T, Castro JL, Shearman MS (2001). Pharmacological knock-down of the presenilin 1 heterodimer by a novel gamma -secretase inhibitor: implications for presenilin biology. J. Biol. Chem., 276:45394–45402.
6. Shearman MS, Beher D, Clarke EE, Lewis HD, Harrison T, Hunt P, Nadin A, Smith AL, Stevenson G, Castro JL (2000.) L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry, 38:8698–8704.
7. Brown MS, Ye J, Rawson RB, Goldstein JL (2000). Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell, 100:391–398.
8. Hardy J, Selkoe DJ (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297(5580):353-356.
9. Mumm JS, Kopan R (2000) Notch signaling: from the outside in. Dev. Biol., 228:151-165

Please visit our Stumbleupon Profile Bio-Synthesis

For more detail regarding Peptide please visit here : Custom Peptide Synthesis

Malaria Peptides

Definition
Malaria is spread by Anopheles mosquitoes, the protozoan parasite grows and multiplies within erythrocytes in its asexual cycle. Different malaria peptides were isolated by human antibodies in plasma samples of individuals exposed to chronic malaria.

Discovery
The first approach of a malaria peptide vaccine was a polymeric chimeric molecule named SPf66, which conferred limited protective efficacy in monkey and human trial 1. Apical membrane antigen-1 is a protein found in the merozoite stage of the malaria parasite Plasmodium falciparum and has been shown to be critical in the invasion of host erythrocytes. Using a random peptide library displayed on the surface of phage, several peptides were identified which specifically recognized and bound to P. falciparum antigen 2. Different malaria peptide specific antibodies were obtained both by affinity-purification from malaria immune sera and by immunization of mice and these peptide candidates are used as vaccine candidates for malaria. Malaria peptides that are used as therapeutic purpose are Malaria CSP (334 - 342), Malaria aspartyl proteinase FRET substrate I, MSP - 1 P2, Malaria merozoite surface peptide – 1, peptides from circumsporozoite (CS) Protein, hemoglobin, 3037a etc. 3,4,5,6.

Structural Characteristics
These are smaller peptides of different sizes. The sequence of Malaria CSP (334 - 342) is H - Tyr - Leu - Lys - Lys - Ile - Lys - Asn - Ser - Leu – OH. MSP - 1 P3, Malaria Merozoite Surface Peptide – 1 sequence is H - Lys - Leu - Asn - Ser - Leu - Asn - Asn - Pro - His - Asn - Val - Leu - Gln - Asn - Phe - Ser - Val - Phe - Phe - Asn - Lys – OH. The amino acid sequence of Hemoglobin, 3037a, Malaria FRET Substrate II—is DABCYL - GABA - Glu - Arg - Met - Phe - Leu - Ser - Phe - Pro – EDANS. The immunodominant T cell epitope of the merozoite antigen ring-infected erythrocyte surface antigen sequence is H-Leu-Gly-Arg-Ser-Gly-Gly-Asp-Ile-Ile-Lys-Lys-Met-Gln-Thr-Leu-OH 3,4,5,6.

Mode of Action
Malaria peptides has been shown to accelerate the humoral antibody immune responses and as a free peptide increase the protective efficacy of cellular immune response and sustain the immunity for a longer time against malaria A. Peptides copying malaria protein sequences often stimulate human CD4+ T cells and it was thought that they represented T cell epitopes present in the parasite and may thus have particular relevance to malaria vaccine development. A 15 residue peptide (PP1) inhibited falcipain-2 enzyme of Plasmodium falciparum activity in vitro. PP1 fused with Antennapedia homeoprotein internalization domain blocked hemoglobin hydrolysis, merozoite release and markedly inhibited Plasmodium falciparum growth and maturation 7. A peptide derived from the proregion of falcipain-2 that blocks late-stage malaria parasite development in RBCs, suggesting the development of peptide and peptidometric drugs against the human malaria parasite 2.

Functions
Malaria CSP (334 - 342) - This is amino acids 334 to 342 fragment of malaria CSP derived from malaria circumsporozoite protein. It is commonly used as a control peptide for melanoma vaccine studies 8.

Malaria Aspartyl Proteinase FRET Substrate I- A useful fluorogenic substrate for the continuous assay of malaria aspartyl proteinase.

MSP - 1 P2, Malaria Merozoite Surface Peptide - 1- This peptide is a fragment of malaria Merozoite Protein 1, MSP-1 (codons 250–271), a malaria vaccine candidate designated P2. It is used to assess T cell response to N-terminal region of MSP-1 4.

MSP - 1 P3, Malaria Merozoite Surface Peptide - 1-This N-terminal region fragment of Malaria, Merozoite Surface Protein (codons 1101–1121), is a malaria vaccine candidate designated as P3. It is used to assess T cell response to the N-terminal region of major merozoite surface protein 1 (MSP-1).

Hemoglobin, 3037a, Malaria FRET Substrate II- The sequence of this peptide is based on the primary site of cleavage within hemoglobin (Hb). This peptide was used to characterize the molecular mechanism underlying Hb degradation by plasmepsin II (PM II). N-terminal (GABA) extension results in higher maximal velocity and dramatic concentration-dependent substrate inhibition 5.

Circumsporozoite (CS) Protein Sequence-This cell-adhesive motif in region II of malarial circumsporozoite protein has also been found in thrombospondin, properdin, and in a blood-stage antigen of Plasmodium falciparum. It was shown to be the critical sequence for the observed cell-adhesive properties 9.

RESA Peptides-This peptide is identical to the immunodominant T cell epitope of the merozoite antigen ring-infected erythrocyte surface antigen Pf155/RESA in its nonrepeated amino-terminal region (residues 181-195) 10.

Malaria Aspartyl Proteinase Substrate- Useful peptide substrate for a continuous fluorescence-based assay of the malaria aspartyl proteinase. The peptide sequence is derived from the cleavage site present in haemoglobin 11.

References
1.Moorthy VS, Good MF, Hill AV (2004). Malaria vaccine developments. Lancet., 363(9403):150-156.
2.Scanlon D, Harris KS, Coley AM, Karas JA, Casey JL, Hughes AB, Foley M (2008). Comprehensive N-Methyl Scanning of a Potent Peptide Inhibitor of Malaria Invasion into Erythrocytes Leads to Pharmacokinetic Optimization of the Molecule. International Journal of Peptide Research and Therapeutics, 14(4):381-386.
3.Yamshchikov GV, Mullins DW, Chang CC, Ogino T, Thompson L, Presley J, Galavotti H, Aquila W, Deacon D, Ross W, Patterson JW, Engelhard VH, Ferrone S, Slingluff CL Jr. (2005). Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol., 174(11):6863-6871.
4.King CL, Malhotra I, Wamachi A, Kioko J, Mungai P, Wahab SA, Koech D, Zimmerman P, Ouma J, Kazura JW.(2002). Acquired immune responses to Plasmodium falciparum merozoite surface protein-1 in the human fetus. J. Immunol., 168(1):356-64.
5.Istvan E, Goldberet D (2005). Distal Substrate Interactions Enhance Plasmepsin Activity. The Journal of Biological Chemistry, 280:6890-6896.
6.Savi P, Bernat A, Lalé A, Roque C, Zamboni G, Herbert JM (2000). Effect of aspirin on platelet desaggregation induced by SR121566, a potent GP-IIb/IIIa antagonist. Platelets, 11(1):43-48
7.Korde R, Bhardwaj A, Singh R, Srivastava A, Chauhan VS, Bhatnagar RK, Malhotra P (2008). A prodomain peptide of plasmodium falciparum cysteine protease(falcipain-2) inhibits malaria parasite development. J. Med. Chem., 51(11): 3116–3123.
8.Blum-Tirouvanziam U, Servis C, Habluetzel A, Valmori D, Men Y, Esposito F, Del Nero L, Holmes N, Fasel N, Corradin G (1995). Localization of HLA-A2.1-restricted T cell epitopes in the circumsporozoite protein of Plasmodium falciparum. J. Immunol., 154(8):3922-3931.
9.Flotow H, Leong CY, Buss AD (2002). Development of a plasmepsin II fluorescence polarization assay suitable for high throughput antimalarial drug discovery. J Biomol Screen., 7(4):367-371.
10. Chougnet C, Troye-Blomberg M, Deloron P, Kabilan L, Lepers JP, Savel J, Perlmann P (1991). Human immune response in Plasmodium falciparum malaria. Synthetic peptides corresponding to known epitopes of the Pf155/RESA antigen induce production of parasite-specific antibodies in vitro. J. Immunol., 147(7):2295-2301.
11. Jiang S, Prigge ST, Wei L, Gao Ye, Hudson TH, Gerena L, Dame JB, Kyle DE (2001). New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins. Antimicrob Agents Chemother., 45(9):2577-2584.

Please visit our Stumbleupon Profile Bio-Synthesis

For more detail regarding Peptide please visit here : Custom Peptide Synthesis

Monday, February 1, 2010

Human Rhinovirus-14 (HRV14) 3C Protease Substrates

Definition
The human rhinoviruses (HRVs), implicated as the major causative agents of upper respiratory tract infections collectively known as the common cold, belong to the largest genus of the picornavirus family. Small plus-strand Human rhinoviruses (HRVs), encode a single open reading frame which is translated into a single large polyprotein with a size of 220 kDa. Maturation cleavage of the polyprotein to generate functional viral proteins is mainly performed by two virally encoded proteases, designated 2A and 3C.

Discovery
The first cleavage is catalyzed by the 2A protease, which takes place at the junction of capsid protein VP1 and the N terminus of the 2A protease itself, separates the viral capsid from the nonstructural proteins. Most of the remaining cleavages are further processed by either the 3C protease or its precursor 3CD enzyme 1,2.

Structural Characteristics
From a structural point of view, rhinovirus 3C proteins display a strong similarity to trypsin-like serine proteases, 3C contains a cysteine as the active site nucleophile. The X-ray crystal structures of 3C proteases from both hepatitis A virus and HRV14 have been solved, revealing their structural similarity to the typical serine proteases 3. Colorimetric assay for 3C using peptides suggests amino acids downstream from the original cleavage site have all been replaced with a chromophoric p-nitroaniline moiety which is directly linked to the bond undergoing enzymatic cleavage, thereby generating a new cleavage site Gln-pNA for the enzyme 4.Cleavage by the 3C proteinase are predicted to occur at a Gln-Gly junction. The hydrolysis was shown (by reverse phase fast protein liquid chromatography and amino acid analysis) to occur specifically at the Gln-Gly bond in each of the peptides. The ready availability of such convenient substrates facilitated the further characterization of the 3C proteinase 5.

Mode of Action
The ability of the HRV-14 3C proteinase to hydrolyse the synthetic peptides was inhibited if a Cys~Ser(146) mutation was introduced into the protein. Studies with known proteinase inhibitors substantiated the conclusion that the HRV- 14 3C protein appears to be a cysteine proteinase and that the Cys residue at position 146 may be the active site nucleophile 5. Kinetic parameters of 3C protease toward p-nitroanilides (pNA) peptides have been measured and analyzed. The pNA peptides have been modeled within the active site of the 3C protease to investigate the ability of the pNA group to act as a replacement for Gly-Pro in the prime side. Hydrolysis of these pNA peptides by 3C at the newly formed scissile bond releases free p-nitroaniline which is yellow-colored and can be continuously monitored at a visible wavelength 3. Compound LY343814, one of the most potent inhibitors against HRV14 3C protease, had an antiviral 50% inhibitory concentration of 4.2 µM in the cell-based assay. Results suggest that the antiviral activity associated with these compounds might result from inactivation of both 2A and 3C proteases in vivo. Since the processing of the viral polyprotein is hierarchical, dual inhibition of the two enzymes may result in cooperative inhibition of viral replication 4.

Functions
Drug development, the 3C proteases encoded by HRV are attractive targets for antiviral drug development due to their important roles in viral replication. The HRV-14 3C proteinase probably plays animportant role, analogous to that implied for the poliovirus 3C proteinase, in the replication of the virus and thus represents a potential target for antiviral chemotherapy 6.

RNA binding, in addition to its proteolytic activity, viral 3C protease has been shown to be a RNA-binding protein and may be involved in formation of the viral replication complex .

Serine protease, as illustrated by its crystal structure, HRV 3C protease represents a novel class of cysteine protease that contains a cysteine as the active site nucleophile but is structurally like a serine protease 7.

References
1.Palmenberg AC (1990). Proteolytic procession of picornaviral polyprotein. Annu. Rev. Microbiol., 44:603–623.
2.Porter AG (1993). Picornavirus nonstructural proteins: emerging roles in virus replication and inhibition of host cell functions. J. Virol., 67:6917–6921.
3.Malcolm BA (1995). The picornaviral 3C proteinases: cysteine nucleophiles in serine proteinase folds. Protein Sci., 4:1439–1445.
4.Wang QM, Johnson RB, Cox GA, Villarreal EC, Loncharich RJ (1997). A continuous colorimetric assay for rhinovirus-14 3C protease using peptide
5.David C, LONG AC, Kay J, Dunn BM, Cameron JM (1989). Hydrolysis of a Series S of synthetic Peptide
6.Leong LE, Walker PA, Porter AG (1993). Human rhinovirus-14 protease 3C (3Cpro) binds specifically to the 5'-noncoding region of the viral RNA. Evidence that 3Cpro has different domains for the RNA binding and proteolytic activities. J. Biol. Chem., 268: 25735–25739.
7.Bazan JF, Fletterick RJ (1988). Viral cysteine proteases are homologous to the trypsin-like family of serine proteases: structural and functional implications.PNAS., 85:7872–7876.
p-nitroanilides (pNA) as substrates p-nitroanilides as substrates. Anal Biochem., 252(2):238-245. Substrates by the Human Rhinovirus 14 3C Proteinase, Cloned and Expressed in E coli. J. gen. Virol., 70: 2931-2942.

For more detail regarding Peptide please visit here : Custom Peptide Synthesis

Herpes Simplex Virus (HSV) Peptides

Definition
Herpes simplex virus (HSV) is a lytic virus. Infection of cells with the HSV leads to a gradual inhibition of cell-specific protein synthesis and a concomitant increase in the rate of synthesis of virus-specific proteins and peptides. Several interactions between HSV proteins have been proposed as attractive targets for antiviral drug discovery.

Discovery
JP Vasilakos in 1993 used a short synthetic peptide representing amino acid residues 497-507 from HSV-1 glycoprotein B to induce Cytotoxic T cells. C57BL/6 mice were immunized with a single dose of a short synthetic peptide representing amino acid residues 497-507 from HSV-1 glycoprotein B. The CTL were CD8+ and H-2b restricted. They were capable of lysing target cells exogenously sensitized with peptide or endogenously processed glycoprotein B 1. Paradis H in 1991 identified a nonapeptide, HSV R2-(329-337), corresponding to the subunit 2 (R2) carboxyl terminus of HSV ribonucleotide reductases, specifically inhibits this enzyme activity 2. HSV envelope glycoproteins are the prime targets of adaptive antiviral immunity. Three overlapping peptides showed ability to stimulate immunity which cross-reacts with HSV-1 3.

Structural Characteristics
Sequence of HSV-1 Glycoprotein (gB) (497-507) is H-Thr-Ser-Ser-Ile-Glu-Phe-Ala-Arg-Leu-Gln-Phe-OH. This peptide represents a H-2Kb T cell epitope of HSV-1 gB. It activates CD8+ cytotoxic T lymphocytes in vivo in a manner independent of CD4+ T cells. HSV R2-(329-337) is a nine amino acid peptide, this peptide was rapidly degraded by proteases present in the partially purified enzyme extract. The main process of proteolysis involves the successive removal of Tyr329 and Ala330, which corresponds to an aminopeptidase activity 2.

Mode of action
CTL primed with custom peptide sequence 497-507 from HSV-1 glycoprotein B produce an anamnestic response in vivo upon peptide challenge. The requirement of CD4+ T cells for CD8+ CTL activation was shown by depleting CD4+ cells in vivo with GK1.5 mAb. CD4+ T cell depletion did not abrogate CTL generation. These results suggest that glycoprotein B peptide 497-507 activates CD8+ CTL in vivo in a manner independent of CD4+ T cells 1. Nx-acetylation, a modification known to protect nonapeptide, HSV R2-(329-337), against aminopeptidase attacks, greatly improved the proteolytic resistance of HSVs 2.

Two peptides, the gB 18-mer and 20.1-mer, were recognized by MAb B6 and HSV-immune antibody but were unable to stimulate virus-neutralizing antibody or serum able to protect against zosteriform spread in vivo. The 20.2-mer peptide, however, which was not recognized by MAb B6 or HSV-generated immune antibody, stimulated the production of neutralizing antibody and serum able to protect against zosteriform spread 3.

A synthetic peptide derived from the secreted portion of HSV type 2 glycoprotein G, denoted gG-2p20, which has proinflammatory properties in vitro. The gG-2p20 peptide, corresponding to aa 190–205 of glycoprotein G-2, was a chemoattractant for both monocytes and neutrophils in a dose-dependent fashion, and also induced the release of reactive oxygen from these cells. The receptor mediating the responses was identified as the formyl peptide receptor. The gG-2p20-induced activation of phagocytes had a profound impact on NK cell functions. The reactive oxygen species produced by gG-2p20-activated phagocytes both inhibited NK cell cytotoxicity and accelerated the apoptotic cell death in NK cell-enriched lymphocyte populations 4.

Functions
Cellular and humoral immunity, investigation of the immune response to herpes simplex virus (HSV) has indicated that certain viral envelope glycoproteins, especially gB, gC, and gD, generate both cellular and humoral immunity 5,6.

Host cell entry, glycoproteins B and D, essential for virus entry into host cells, act as protective immunogens in animals when introduced in recombinant virus vectors, as purified proteins, or in transfected L cells 7.

Neutralizing antibody, three overlapping peptides, corresponding to the wild-type gB-1 sequence amino acids 63 to 110 have the ability to stimulate immunity in mice which cross-reacts with HSV-1. One peptide was able to generate HSV-1 neutralizing antibody which protected in the murine zosteriform spread model.

CCAP, the complex of native cytokines and antimicrobial peptides (CCAP or Superlymph) proved to inhibit the HSV reproduction in vitro. Protegrines, as a CCAP component, were active against the virus 8.

References
1.Vasilakos JP, Michael JG (1993). Herpes simplex virus class I-restricted peptide induces cytotoxic T lymphocytes in vivo independent of CD4+ T cells. J. Immunol., 150(6):2346-2355.
2.Paradis H, Langelier Y, Michaud J, Brazeau P, Gaudreau P (1991). Studies on in vitro proteolytic sensitivity of peptides inhibiting herpes simplex virus ribonucleotide reductases lead to discovery of a stable and potent inhibitor. Int J Pept Protein Res., 37(1):72-79.
3.Mester JC, Highlander SL, Osmand AP, Glorioso JC, Rouse BT (1990). Herpes Simplex Virus Type 1-Specific Immunity Induced by Peptides Corresponding to an Antigenic Site of Glycoprotein B. J. Virology., 64(11):5277-5283.
4.Bellner L (2005). A Proinflammatory Peptide from Herpes Simplex Virus Type 2 Glycoprotein G Affects Neutrophil, Monocyte, and NK Cell Functions. The Journal of Immunology, 174:2235-2241.
5.Vestergaard BF (1980). Herpes simplex virus antigens and antibodies: a survey of studies based on quantitative immunoelectrophoresis. Rev. Infect. Dis., 2:899-913.
6.Zarling JM (1986). T cell-mediated immunity to herpes simplex viruses, p. 103-114. In C. Lopez and B. Roizman (ed.), Human herpesvirus infections. Raven Press, New York.
7.Corey L, Spear PG (1986). Infections with herpes simplex viruses. N. Engl. J. Med., 314: 686-691.
8.Kovalchuk LV, Gankovskaya LV, Gankovskaya OA, Lavrov VF (2007). Herpes simplex virus: treatment with antimicrobial peptides. Adv Exp Med Biol., 601:369-376.

Please visit our Stumbleupon Profile Bio-Synthesis

For more detail regarding Peptide please visit here : Custom Peptide Synthesis